These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33203674)

  • 1. Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division.
    Replogle JM; Zhou W; Amaro AE; McFarland JM; Villalobos-Ortiz M; Ryan J; Letai A; Yilmaz O; Sheltzer J; Lippard SJ; Ben-David U; Amon A
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30566-30576. PubMed ID: 33203674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HZ08 reverse the aneuploidy-induced cisplatin-resistance in Gastric cancer by modulating the p53 pathway.
    Tang X; Hu G; Xu C; Ouyang K; Fang W; Huang W; Zhang J; Li F; Wang K; Qin X; Li Y
    Eur J Pharmacol; 2013 Nov; 720(1-3):84-97. PubMed ID: 24183976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
    Zheng H; Wang JJ; Yang XR; Yu YL
    World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel.
    Wang Q; Lu F; Lan R
    Mol Biosyst; 2017 Sep; 13(10):2125-2134. PubMed ID: 28825433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirally mediated p53 overexpression diversely influence the cell cycle of HEp-2 and CAL 27 cell lines upon cisplatin and methotrexate treatment.
    Kraljević Pavelić S; Marjanović M; Poznić M; Kralj M
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1747-61. PubMed ID: 19548002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mediates hydroxyurea resistance in aneuploid cells of colon cancer.
    Fang X; Yin H; Zhang H; Wu F; Liu Y; Fu Y; Yu D; Zong L
    Exp Cell Res; 2019 Mar; 376(1):39-48. PubMed ID: 30684461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
    Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy.
    Compagnin C; Mognato M; Celotti L; Canti G; Palumbo G; Reddi E
    Cell Prolif; 2010 Jun; 43(3):262-74. PubMed ID: 20546244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
    Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM
    J Ovarian Res; 2014; 7():45. PubMed ID: 24795781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
    Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW
    Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptation to Endoplasmic Reticulum Stress Enhances Resistance of Oral Cancer Cells to Cisplatin by Up-Regulating Polymerase η and Increasing DNA Repair Efficiency.
    Chen CY; Kawasumi M; Lan TY; Poon CL; Lin YS; Wu PJ; Chen YC; Chen BH; Wu CH; Lo JF; Weng RR; Sun YC; Hung KF
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [P53 mutations, asset or disadvantage for cancer chemotherapy].
    Jacquemin-Sablon A
    Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS; Taylor DD; Gercel-Taylor C
    Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.
    Vanas V; Haigl B; Stockhammer V; Sutterlüty-Fall H
    PLoS One; 2016; 11(8):e0161023. PubMed ID: 27513462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.